Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Aug 14, 2024
- Pharmaceuticals
- R&D
Galderma’s Announcement Regarding Nemolizumab (FDA Approval for the Treatment of Prurigo Nodularis)
TOKYO, August 14, 2024 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Galderma issued a press release on August 13 that the U.S. Food and Drug Administration (FDA) has approved the humanized anti-human IL-31 receptor A monoclonal antibody Nemluvio® (generic name: nemolizumab) for the treatment of adults with prurigo nodularis (PN). Nemolizumab was created by Chugai, and its clinical development outside Japan is being conducted by Galderma.
Please refer to the link below for details of the Galderma’s press release:
Galderma receives U.S. FDA approval for Nemluvio® (nemolizumab) for adult patients living with prurigo nodularis
https://www.galderma.com/news/galderma-receives-us-fda-approval-nemluvior-nemolizumab-adult-patients-living-prurigo
Trademarks used or mentioned in this release are protected by laws.
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Hideki Sato
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp
